Ulcerative Colitis (UC): Optimizing Pharmacotherapeutic Management Strategies

Details

Inflammatory bowel disease (IBD) is a broad term that includes many different forms of inflammatory bowel conditions, the most common of which are ulcerative colitis (UC) and Crohn’s disease (CD), the former of which exclusively affects the colon and rectum. UC occurs more frequently than CD, with an incidence of 1.2 to 20.3 cases per 100,000 persons per year and a prevalence of 7.6 to 246.0 cases per 100,000 per year, as compared to 0.03 to 15.6 and 3.6 to 214.0 per 100,000 for CD. Risk factors include characteristics common in westernized environments and lifestyles, including smoking, diets high in fat and sugar, medication use, stress, and high socioeconomic status.

Target Audience:

HCPs specializing in: gastroenterology, internal medicine; nurse practitioners, physician assistants, and pharmacists who specialize in gastroenterology; and those who otherwise commonly care for or clinically encounter patients with UC.

By the end of the session the participant will be able to:

• Describe the burden of disease UC represents to patients.
• Identify the present treatment options currently available for management of UC and apply them to patient cases using evidence-based medicine.
• Identify new and emerging therapies for the treatment of UC.
• Evaluate a treatment plan for a specific patient based on severity of UC to optimize safety, efficacy, and cost-efficacy, suggesting modifications for improvement.